Nanomedicine News RSS Feed - Nanomedicine

TKM-Ebola Investigational New Drug Application Modified to Partial Clinical Hold

TKM-Ebola Investigational New Drug Application Modified to Partial Clinical Hold

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food & Drug Administration (FDA) has verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola Investigational New Drug Application (IND) to a partial clinical hold. This action enables the potential use of TKM-Ebola in individuals infected with Ebola virus. [More]
NIH/NCI Awards $1.15 Million Grant for Study on ‘Cancer Nanomedicine Co-ops for Undergraduate Research Experiences’

NIH/NCI Awards $1.15 Million Grant for Study on ‘Cancer Nanomedicine Co-ops for Undergraduate Research Experiences’

Physics Professor Srinivas Sridhar has received a $1.15 million grant titled “CaNCURE: Cancer Nanomedicine Co-ops for Undergraduate Research Experiences” funded by the National Cancer Institute and the National Institutes of Health. This 5-year grant is a collaboration between Northeastern University and Dana-Farber/Harvard Cancer Center. [More]
Oraya Awarded NIH Grant to Investigate Stereotactic Radiotherapy and Gold Nanoparticle Treatment for Wet AMD

Oraya Awarded NIH Grant to Investigate Stereotactic Radiotherapy and Gold Nanoparticle Treatment for Wet AMD

Oraya® Therapeutics, Inc. announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a low voltage stereotactic radiotherapy, and gold nanoparticles can further enhance the treatment of wet age-related macular degeneration (Wet AMD). [More]
Gold Nanoparticles and Targeted Laser Therapy used to Treat Labradoodle with Nasal Adenocarcinoma

Gold Nanoparticles and Targeted Laser Therapy used to Treat Labradoodle with Nasal Adenocarcinoma

When Michael and Sandra Friedlander first came to the Virginia-Maryland College of Veterinary Medicine three years ago with their dog, Grayton, they learned some bad news: Grayton had nasal adenocarcinoma, a form of cancer with a short life expectancy. [More]
NanoViricides Announces Restart of Drug Development Program to Combat Ebola

NanoViricides Announces Restart of Drug Development Program to Combat Ebola

NanoViricides, Inc. (the “Company”) reports that it is restarting its drug development program to combat Ebola virus infections. [More]
Researchers Employ Radioactive Labelling to Track Key Materials in Nanomedicines

Researchers Employ Radioactive Labelling to Track Key Materials in Nanomedicines

The University of Liverpool has been awarded £2 million to become a leading centre in the UK for tracking the fate in the body of materials used in breakthrough medicines. [More]
Biodegradable, Nanoscale Thin Films Release Drugs in Steady Doses Over a Long Period of Time

Biodegradable, Nanoscale Thin Films Release Drugs in Steady Doses Over a Long Period of Time

About one in four older adults suffers from chronic pain. Many of those people take medication, usually as pills. But this is not an ideal way of treating pain: Patients must take medicine frequently, and can suffer side effects, since the contents of pills spread through the bloodstream to the whole body. [More]
Kala Initiates Nanotechnology-Based LE-MPP Phase 2 Clinical Trial

Kala Initiates Nanotechnology-Based LE-MPP Phase 2 Clinical Trial

Kala Pharmaceuticals, Inc., a leading developer of innovative nanotechnology-based ophthalmic products leveraging the company’s proprietary Mucus Penetrating Particle (MPP) platform, today announced the initiation of a Phase 2 clinical trial (KPI-121-C-004) to evaluate KP-121, the company’s loteprednol etabonate MPP (“LE-MPP”) drug product, in patients with intraretinal or subretinal fluid secondary to retinal vein occlusion (RVO) or diabetic macular edema (DME). [More]
IBN Develops Gold Nanoprobe Technology for Unlocking Genetic Profiles

IBN Develops Gold Nanoprobe Technology for Unlocking Genetic Profiles

A fast and cost-effective genetic test to determine the correct dosage of blood thinning drugs for the treatment of stroke, heart problems and deep vein thrombosis has been developed by researchers at the Institute of Bioengineering and Nanotechnology (IBN). Using gold nanoprobes, this new technology offers personalized healthcare based on the genetic profile of the patients. [More]
Genomic Medicine Innovator to Serve as Director for Providence Cancer Services and Bioinformatics

Genomic Medicine Innovator to Serve as Director for Providence Cancer Services and Bioinformatics

Today, Providence Health & Services announced that Dr. Patrick Soon-Shiong, a physician, surgeon and scientist known globally for applying collaborative science and technology to improve the health of patients battling life-threatening disease, will serve as the health care system's new global director for cancer services and bioinformatics. [More]